Media Contact
+886-2-2627-2707+1-415-655-6603 info@altrubio.com
Media Contact
+886-2-2627-2707AltruBio Announces Enrollment of First Patient in Phase 2 Clinical Program of ALTB-268 for the Treatment of Ulcerative Colitis
ISPE─ISPE Announces Leaders from Health Canada, AltruBio, AstraZeneca, Gilead, Lonza, Lyndra, and More to Speak at the 2023 ISPE Annual Meeting & Exp
AltruBio Announces FDA Clearance of IND Application for Immune Checkpoint Enhancer ALTB-268 to initiate a Phase 2 Clinical Trial for the Treatment of Ulcerative Colitis
STIFEL Financial Corp.─Virtual 2023 Stifel Immunology and Inflammation Summit
AltruBio Announces Positive Topline Data from Phase 1 Trial of Immune Checkpoint Enhancer ALTB-268 for the Treatment of Ulcerative Colitis
AltruBio to Present at the Federation of Clinical Immunology Societies (FOCIS) 2023 Annual Meeting
top